

May 23, 2022

National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex Bandra (E)
Mumbai – 400 051

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

Subject: Corporate Presentation Q4 & FY22

Dear Sir/ Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Listing Regulations), please find attached herewith Corporate Presentation of the Company for Q4 & FY22, which the Company proposes to share with analysts/ investors.

We request you to please take the same on record.

Thanking You,

Yours Faithfully,

For **Dr. Lal PathLabs Limited**



Rajat Kalra

Company Secretary and Legal Head

Encl.: As above





Dr. Lal PathLabs Limited (DLPL)

ENABLING
HEALTHIER
LIVES

Corporate Presentation

May 2022

Disclaimer

By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations:

The information in this presentation has been prepared by Dr. Lal PathLabs Limited (the "Company") for use in presentations by the Company at analyst and investor meetings and does not constitute a recommendation regarding the securities of the Company. No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information, or opinions contained herein. Neither the Company nor any of its advisors or representatives shall have any responsibility or liability whatsoever (for negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with this presentation. The information set out herein may be subject to updating, completion, revision, verification and amendment and such information may change materially. Neither the Company nor any of its advisors or representatives is under any obligation to update or keep current the information contained herein. The information communicated in this presentation contains certain statements that are or may be forward looking. These statements typically contain words such as "will", "expects" and "anticipates" and words of similar import. By their nature forward looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. Any investment in securities issued by the Company will also involve certain risks. There may be additional material risks that are currently not considered to be material or of which the Company and its advisors or representatives are unaware. Against the background of these uncertainties, readers should not unduly rely on these forward looking statements. The Company, its advisors and representatives assume no responsibility to update forward-looking statements or to adapt them to future events or developments.

This presentation has been prepared for informational purposes only. This presentation does not constitute a prospectus under the (Indian) Companies Act, 2013 and will not be registered with any registrar of companies. Furthermore, this presentation is not and should not be construed as an offer or a solicitation of an offer to buy securities for sale in the India. This presentation and the information contained herein does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities of the Company, nor should it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered, sold or delivered within the United States or to U.S. persons absent from registration under or an applicable exemption from the registration requirements of the United States securities laws. This presentation and the information contained herein is being furnished to you solely for your information and may not be reproduced or redistributed to any other person, in whole or in part. In particular, neither the information contained in this presentation nor any copy hereof may be, directly or indirectly, taken or transmitted into or distributed in the U.S., Canada, Australia, Japan or any other jurisdiction which prohibits the same except in compliance with applicable securities laws. Any failure to comply with this restriction may constitute a violation of the United States or other national securities laws. No money, securities or other consideration is being solicited, and, if sent in response to this presentation or the information contained herein, will not be accepted.

By reviewing this presentation, you are deemed to have represented and agreed that you and any person you represent are either (a) a qualified institutional buyer (within the meaning of Regulation 144A under the Securities Act) or (b) not a U.S. person (as defined in Regulation S under the Securities Act) and are outside of the United States and not acting for the account or benefit of a U.S. person.

Table of Contents

Company Overview

4

Investment Highlights

9

Q4 & FY22 Highlights

23

DLPL Strategy for Future Growth

33



Corporate Overview

[Dr. Lal PathLabs at a glance](#)

[Our Evolution](#)

[Dr. Lal PathLabs overview](#)

[Experienced Management team](#)

Dr. Lal PathLabs – At a Glance

India's Leading & Trusted
Diagnostics Company

70+ years of experience
in the field of diagnostics

100 Mn patients serviced
in last 5 years

31 NABL accredited Labs;
National Reference Lab
accredited by CAP

**Largest*
diagnostics
chain in the
country with
PAN India
presence and
consistent track
record of
quality and
growth**

20%

3 Year Revenue
CAGR

20%

3-Year PAT
CAGR

120%

Equity Dividend
for FY 21-22

~44%

ROCE
Excl. Cash &
Investments

Rs. 344 crore (Net)

Cash & Investments as on
31st Mar, 22

277

Labs;
Geographically
spread out
network

4,731

Patient Service
Centres (PSC's)

5,113

Pathology &
Radiology tests;
Comprehensive
Test menu

As on March 31, 2022

*Largest on the basis of revenue and presence

Note: Figures includes Suburban Diagnostics w.e.f. 12th November 2021

Our Evolution

1949 – 2005

Foundation

- **1949:** Founded by Dr. Major S. K. Lal
- **1995:** Company incorporated as Dr. Lal PathLabs Private Ltd.
- **2000:** Three clinical labs receive NABL¹ accreditation
- **2001:** Received ISO 9001:2008 certification
- **2002:** Received 'International Accreditation' from CAP²

2005 – 2010

Building capabilities for scale up

- **2005:** onwards: Investment by WestBridge Capital
- **2008:** Acquisition of Paliwal Medicare Private Limited and Paliwal Diagnostics Private Limited
- **2010:** National Reference Lab set up in Delhi

2010 – 2015

Strong position in North India, building network in other geographies

- Investment by TA Associates
- Clinical laboratories expansion in North region
- Growing the business in East region
- Entry into the South and West regions
- Multiple acquisitions to scale network
- Successful IPO listing in Dec 2015

2015 -2020

Higher contribution from Rest of India, Commissioned state of the art Kolkata Reference Lab

- Higher contribution from Rest of India business & focus on bundled test program "Swasthfit"
- Successful commissioning of Regional Reference Lab at Kolkata in 2018
- Inorganic growth through acquisition of laboratories in Western & Southern India

2020 onwards

Pan India Player – Acquired Suburban, Building South Ecosystem

- First to set-up RT-PCR testing network in 2020
- Completed acquisition of Suburban Diagnostics in 2021
- Expanded South ecosystem through Bengaluru Reference Lab and network of Hub & Satellite labs
- Established hub labs in North region
- Spearheading investments in Digital and InfoSec

1. NABL: National Accreditation Board for Calibration and Testing Laboratories.

2. CAP: College of American Pathologists.

Dr. Lal PathLabs overview

Established consumer healthcare brand in diagnostic services

Pan-India integrated coverage with **277** clinical labs (including National Reference Lab¹ at Delhi and Regional Ref Lab at Kolkata), **4,731** Patient Service Centers (PSCs) and **10,599** Pick-up Points (PUPs)²

Catalogue of **491** test panels, **2,675** pathology tests and **1,947** radiology and cardiology tests²


Collected and processed **~65.9 mn** samples from **~27.3 mn** patients in FY22; **~49.7 mn** samples from **~20.3 mn** patients in FY21; **~47.7 mn** samples from **~19.4 mn** patients in FY20

Customers include individual patients, corporates and institutions, healthcare providers as well as hospital and clinical labs (lab management)


FY22: Revenue: **INR 2,087.4 Cr.**; EBITDA: **INR 600.4 Cr³** (Margin: **28.8%**); PAT: **INR 350.3 Cr** (Margin: **16.8%**);
FY21: Revenue: **INR 1,581.3 Cr.**; EBITDA: **INR 462.6 Cr³** (Margin: **29.3%**); PAT: **INR 296.5 Cr** (Margin: **18.8%**);

Test Menu

Routine testing



Specialized testing



Accreditations



ISO15189:2007
IS9001:2008
ISO27001:2013

1. Total area of 7,253 square meters
2. As on March 31, 2022.
3. Normalised EBITDA excl ESOP & CSR Cost

Experienced Management team

(Hony.) Brig. Dr. Arvind Lal

Executive Chairman



Dr. Om Manchanda

Managing Director



Dr. Vandana Lal

Whole-time Director



Bharath Uppiliappan

Chief Executive Officer



Ved Prakash Goel

Group Chief Financial Officer



Shankha Banerjee

Chief Executive Officer (Group Cos)



Munender Soperna

Chief Information Officer



Rajat Kalra

Company Secretary and Compliance Officer



Manoj Garg

Group Chief Human Resources Officer






Dr Lal PathLabs

Investment Highlights

Investment Highlights



Indian Healthcare Services is a large and growing opportunity

~1.4 bn

India's expected population in 2025¹

~\$3,400 bn

India GDP in FY23²

2.5%

Government Expenditure on healthcare (as % of GDP) in FY25³


\$372 bn

Expected India's healthcare industry size in CY22³

~62%

Out of pocket expenses to overall healthcare spends⁴

Total Healthcare Expenditure as % of GDP (2019)⁵




India, highly underpenetrated market

Source: (1) NITI Aayog– Policy Recommendations by R. K. Sinha, (2) PHDCCI Report, (3) IBEF, (4) Article by Outlook India, (5) World Bank


Drivers of India diagnostic services market

Diagnostic Services Industry Size




Screening, early detection, and monitoring
reduce downstream costs

Growth Drivers




Diagnostic Services industry continues to remain highly fragmented




Largely fragmented and unorganized

Established reputed consumer healthcare brand in Diagnostic Services




Pillar of a Strong Brand

- Accreditations from CAP, NABL and ISO
- Centrally administered surveillance programs
- Coverage in metros, Tier 1 and Tier 2 cities
- Wide reach through PSCs and PUPs
- 24x7 access including online access and home collection
- Dedicated logistics team



Collection network

LPL's scalable business model provides strategic advantage for expansion and consolidation



Single brand pulls patients

Walk-in customers account for highest share of revenues

Diverse, large customer pool offers monetization opportunities

Digital Touchpoints across patient journey

Digital Point Of Sale Applications

Sample Collection

Logistics



- Phlebo App – Scan lab number, Documentation, Order Closures for home collection
- Phlebo Kiosk – In lab application for Phlebo
- Customer Feedback/NPS Scoring

- Live tracking of samples, inter & intra city, cash collection, dynamic routing, gamification, lab shipments
- Audit


Report Engine

Lab Processing



- Historical Trends
- Cumulative Reporting
- Smart Report
- RPA For Govt. Reporting
- Live Report Status

- Reporting & Analysis
- Instruments integrations
- Quality & Compliance
- Workflow Management



- Patient App/Website – Order Booking, Reports, Find Nearby Center, Test Info, Expected time of report, Live order status, App Notifications
- Partner Portal – Registration, Business snapshots, Report Download, AI enabled Recommendation engine
- Home Collection Portal – Customer Order Booking, Report status
- Seamless Omni channel Experience



Customers



Extending “Digital Properties” to our Partners to enhance Partner Experience

Digital Onboarding


- Self initiated seamless digital onboarding
- Alert center for faster communication
- Tie up with partners for faster Partner setup
- Notifications via SMS & Emails on progress

Reports

- View and download report for patients
- Real time status of the report
- Printing of reports with and without headers
- Blocking of reports for non paying customers
- Send secured and encrypted reports to patients via email

Business Snapshot

- Business analytics on Patients & Revenue
- Insights into what's selling and what not
- Individual tests vs panels sold
- Daily, weekly, monthly & yearly numbers



Registration

- Integrated patient order booking workflow with historical data
- AI/ML enabled recommendation engine for upselling & cross selling opportunities
- Notifications to customer on booking, invoicing and report status

Quality & Compliance

- Digital compliance & quality checklist
- Document management for all compliance related documents
- Mobile enabled app for completion of trainings
- Vials information at every test during registration to reduce errors

Revenue

- Real time ledgers and Invoices
- Revenue share details
- Payment history for payments made to clear credit outstanding

Control Tower Implementation

“Control Tower” implementation provides a complete visibility of Patient samples across the sample processing lifecycle. The insights will help the business users to reduce delay and improve processing leading to better customer service.

Control Tower Teams

Key Highlights

Cloud Data Lake



Front Desk

Failure Indicator Areas - Home Collection, Credit management & Sample/Registration Deficiency



Logistics

Failure Indicator Areas - Unregistered Samples, Bagging & Shipping of samples



Lab Operations

Failure Indicator Areas - samples scan-in & scan-out, Shipment creation, Report Validation



Digital


Failure Indicator Areas: Delay in report upload and payment

- Centralized Monitoring Team for “**Control Tower**” Operation
- Real-time information for the delays happening across sample processing lifecycle with actionable insights
- Quick decision making
- Drill-down level information available till last leaf i.e. Lab Number / Field Executive
- Information accessible based on Roles & Rights
- Overall design is based on “**Mobile First**” Approach

- Future ready Cloud architecture with easily scalable and upgradable
- Data for “**Control Tower**” is processed through “**Data Lake**” hosted on Cloud
- “**Data Lake**” helps in consolidating the data from multiple source systems and provides easy access information securely


Scalable Model integrated through centralized IT & digital platforms allows for network expansion

Integrated National Network...




Network Expansion


No. of Clinical Laboratories*



No. of PSCs



No. of PUPs



* Notes


- Includes National Reference Laboratory and Regional Reference Labs in Kolkata & Bengaluru
- Includes 38 Labs, 177 PSC's and 983 PUP's of Suburban Diagnostics

Attractive operating metrics

No. of patients

(Mn)


CAGR: 19%



No. of samples

(Mn)


CAGR: 18%



Total Revenue

(INR Cr.)


CAGR: 25%



Non-covid Revenue

(INR Cr.)

CAGR: 13%



- Consumer brand and network expansion driving patient volumes

- Increase in samples with patient volumes growth

- FY22 Revenues increased on account of :
 - Gains in patient volumes at 35%

- Non Covid Revenue growth CAGR at 13%



Note: Results includes Suburban financials wef 12th Nov'21 . On transition from IGAAP to IND AS, revenue adjusted as per IND AS 115.

Robust financial performance

Total Revenue

(INR Cr.)


CAGR: 25%



EBITDA*, PAT and Return on Net Worth

(INR Cr./%)

Normalised EBITDA* (Yellow) Normalised PAT** (Red)



	FY20	FY21	FY22
EBITDA* Margin Before ESOP & CSR	27.5%	29.3%	28.8%
Normalised PAT Margin	17.1%	18.7%	17.7%
RONW	22.7%	25.4%	26.2%

- Growth driven primarily by increasing patient volumes and realization
- Increase in operating margin due to economies of scale and cost efficiencies


* Normalised EBITDA excl. RSU, CSR

**Normalised PBT & PAT excl. notional depreciation on consolidation of Suburban


Note: Results includes Suburban financials wef 12th Nov'21 . On transition from IGAAP to IND AS, revenue adjusted as per IND AS 115.

Robust financial performance (Cont'd)

Fixed Asset Turnover¹ Times



Cash and Cash Equivalents (INR Cr.)



■ Cash and Bank Balance ■ Current Investments

- Self funded growth on account of strong cash flow generation
- Attractive fixed asset turnover ratio given asset-light model
- Current net cash position and internal accruals expected to fund next phase of growth




1. Fixed Asset Turnover = Total Revenue / Net PP&E as per Ind AS



 *Dr Lal PathLabs*

Q4 & FY22 Highlights

FY22 Snapshot







* Normalised EBITDA excl. RSU, CSR

**Normalised PAT excl. notional depreciation on consolidation of Suburban

Note: Results includes Suburban Diagnostics

Q4 FY22 Snapshot



* Normalised EBITDA excl. RSU, CSR

**Normalised PAT excl. notional depreciation on consolidation of Suburban

Note: Results includes Suburban Diagnostics

Overview of Dr. Lal PathLabs

Established brand

Established consumer healthcare brand in diagnostic services



Pan-India integrated coverage

277 clinical labs (including National Reference Lab at Delhi and Regional Reference lab at Kolkata), 4,731 Patient Service Centers (PSCs) and 10,599 Pick-up Points (PUPs)*



Varied Offerings

Catalogue of 491 test panels, 2,675 pathology tests and 1,947 radiology and cardiology tests



Unique and successful operating model

Scalable model integrated through centralised IT platform allows for network expansion




Well-positioned in one of the fastest-growing segments of the Indian healthcare industry

* Includes 38 Labs, 177 PSC's and 983 PUP's of Suburban Diagnostics

As on March 31, 2022

Classification: **Restricted**

Non-COVID, COVID & Allied Revenue



*COVID includes RTPCR and Antibody tests; **COVID Allied 1 includes IL-6 & D-Dimer; ***COVID Allied 2 includes CRP, Ferritin & LDH

Total Covid and Covid allied contribution at 14% in Q4 FY22, 13% in Q4 FY21

Note: Revenue in Q4 22 includes Rs 46 Cr (Non Covid 29.4 Cr, Covid Rs 16.6 Cr) and Q3 22 includes Rs. 49.1 Cr (Non Covid 24.6 Cr, Covid Rs 24.5 Cr) of Suburban wef 12th Nov'21. On transition from IGAAP to IND AS, revenue adjusted as per IND AS 115.

Key Performance Highlights

Q4 FY22 & FY22:

- Revenues up by 12.7% Y-o-Y to Rs. 485.5 crore in Q4 FY22. Revenue up by 32% to Rs 2087.4 crore in FY22
- Normalised EBITDA* is Rs. 130.7 crore, margin of 26.9% in Q4 FY22. In FY22, Normalised EBITDA* is Rs 600.4 crore, margin at 28.8%.
- Normalised Profit After Tax** at Rs. 72.9 crore, margin of 15.0% in Q4 FY22, Normalised PAT** in FY22 is at Rs 369.1 crore, margin of 17.7%

Net Cash and Cash Equivalents at Rs. 344 crore as on March 31, 2022

Witnessed strong trajectory in non-COVID business following ease of mobility restrictions across the country; growth in non-COVID business at 12.2% Y-o-Y

- Revenues from Non-COVID business at Rs 419.7 Cr with 'Swasthfit' contributing 18%
- Enhanced focus on driving volumes while maintaining prices; tactical penetration in West & South through modular cluster city approach playing out well. HUB lab program helping add revenue gains

* Normalised EBITDA excl. RSU, CSR

**Normalised PAT excl. notional depreciation on consolidation of Suburban

Note: Results includes Suburban Diagnostics

Financials


Particulars (Rs. Cr.)	Q4'22	Q4'21	Gr %	FY'22	FY'21	Gr %
Revenue	485.5	431.0	12.7%	2,087.4	1,581.3	32.0%
Expenditure	364.5	308.9		1,526.7	1145.0	
EBITDA	121.1	122.0		560.7	436.3	
Stock based comp., CSR cost	9.6	7.5		39.7	26.3	
Normalised EBITDA	130.7	129.5	0.9%	600.4	462.6	29.8%
<i>Normalised Margins</i>	<i>26.9%</i>	<i>30.1%</i>		<i>28.8%</i>	<i>29.3%</i>	
Net other Income/ (Interest)	0.2	9.1		22.4	35.3	
PBT	83.5	110.8	-24.6%	474.9	394.4	20.4%
<i>Margins</i>	<i>17.2%</i>	<i>25.7%</i>		<i>22.8%</i>	<i>24.9%</i>	
PAT	62.1	85.1	-27.1%	350.3	296.5	18.1%
<i>Margins</i>	<i>12.8%</i>	<i>19.7%</i>		<i>16.8%</i>	<i>18.7%</i>	
EPS (Basic)	7.41	10.10		41.70	35.33	
Normalised PBT*	94.4	110.8	-14.8%	493.8	394.4	25.2%
<i>Margins</i>	<i>19.4%</i>	<i>25.7%</i>		<i>23.7%</i>	<i>24.9%</i>	
Normalised PAT*	72.9	85.1	-14.3%	369.1	296.5	24.5%
<i>Margins</i>	<i>15.0%</i>	<i>19.7%</i>		<i>17.7%</i>	<i>18.7%</i>	

*Normalised PBT & PAT are excl. notional depreciation on consolidation of Suburban

Results includes Suburban financials wef 12th Nov'21. On transition from IGAAP to IND AS, revenue adjusted as per IND AS 115.

Financial Highlights

All figures in Rs. Crore



* Normalised EBITDA excl. RSU, CSR

**Normalised PBT & PAT excl. notional depreciation on consolidation of Suburban

Note: Results includes Suburban financials wef 12th Nov'21 . On transition from IGAAP to IND AS, revenue adjusted as per IND AS 115.

Management Commentary

Commenting on the results announcement, (Hony) Brig. Dr. Arvind Lal, Executive Chairman said:

“India remains a largely underserved market for diagnostics. The scope for growth for companies like ours is huge and we want to leverage our position as a leading player. At Dr. Lal PathLabs, we see ourselves as a progressive brand and have been at the forefront of integrating technology into our business model. This helps us reduce costs as well as provide a more seamless and cohesive experience to our patients. We continue to invest in latest technologies across medical science and patient service in line with our vision of being the most trusted healthcare partner”

Commenting on the results announcement, Dr. Om Manchanda, Managing Director said:


“The acquisition of Suburban Diagnostics has brought Dr. Lal PathLabs brand to the heart of Western market i.e., Maharashtra. And we will work with the Suburban team to leverage the joint expertise and capabilities to create best-in-class proposition and deliver top notch patient experience.

We have demonstrated strong growth in this quarter, which is likely to continue as we realise our growth aspirations in various regions across the country. With one of the strongest digital presence in the Indian diagnostics and healthcare industry, we are well placed to reach more patients and offer them accurate diagnostics at affordable costs.”

Commenting on the results announcement, Mr. Bharath Uppiliappan, Chief Executive Officer said:

“Q4 FY22 started off well, however, the onset of Omicron wave in early part of the quarter impacted Non Covid business which recovered only in second half of the quarter. Our strategic initiatives leveraging digital on patient service levels, geography/tests expansion and channel capability building continue to make good strides. This will enable us to maintain our leadership position for the times to come”

Shareholding as of 31st March, 2022



*Mutual Funds includes Alternate Investment Funds as well




 *Dr Lal PathLabs*

DLPL Strategy for future growth

Vision, Mission & Values

Be the most trusted
healthcare partner,
enabling healthier
lives

To be an undisputed market
leader by providing accessible,
affordable, timely and quality
healthcare, diagnostics, applying
insights and cutting-edge
technology to create value for
all stakeholders



Customer First

Ethics &
Integrity

Quality

Accountability

Empathy &
Compassion

Vibrant Outlook

Target to grow ahead of the industry

Emphasis on digital native approach at front as well as back end


Strongly develop Rest of India geographies, through Regional Reference Labs, Hub Labs and cluster city approach for attractive markets

Deeper Penetration within the North, East, West & Central Indian markets

Higher contribution from bundling of tests – 'Swasthfit'

Evaluate best fit inorganic opportunities in South, and leverage expertise of recently acquired Suburban brand in West



DLPL Strategy for future growth



DLPL Strategy for future growth



Consistent investments in R&D



Genevolve: The Genomics initiative

GENEVOLVE- Genetic Testing Your Smart Choice



New Tests

- 63 New Test Launched- Oncogenomics & Neurogenomics



New Tie-ups

- Caris Inc. (USA)
- Foundation Medicine
- Novartis



ONCOPATH

- Leaders in Oncopath
- In-House Testing Capabilities

Genevolve: Genomics division focuses on Genetic testing

Offers wide range of key tests related to Oncogenomics, Neurogenomics, Rare disease & Pre-natal/ Post-natal

Tests are carried out using cutting edge technologies such as Next Generation Sequencing (NGS), MLPA, ddPCR, FISH & Sanger Sequencing among others

PAN India network of clinical laboratories, collection centers and pick- up points makes Dr. Lal PathLabs the most reliable genetic testing service provider in India

Widest test range solutions for Cancer- Hematological Malignancies, Solid Tumor including multigene panels, Molecular Profiles & Panels in combinations with IHC

In-house adoption of Digital Histopathology

Reporting of Digital Breast cancer Panels using AI based algorithms

Digital Histopathology for remote routine reporting



Opportunities created by Digital Histopathology

- Enhanced access to second opinion, synchronous review of slides
- Enhanced quality of reporting
- Potential for insourcing services
- Leveraging Artificial Intelligence for Histopathology
- Potential for de-centralization of histopathology reporting

Highest Quality Standards in the Industry

Best in the Industry CAP Proficiency Testing Score at 97.9% for National Reference Lab

Consistently high EQAS Performance Testing Score at 98.6% for Satellite Labs

NABL Accreditation granted to 18 Labs for processing Covid-19 samples


Real time quality
control monitoring

Risk based quality
assurance
framework

100+ Quality
improvement
meetings on a daily
basis with the
network partners

Digitally enabled
solutions
implemented for
quality audits and
trainings

Best in class Logistics and Supply Chain management



Enhanced Customer Experience in Home Collection



Auto Routing engine to dynamically allocate the booking to nearest available phlebotomist

Enabled Franchisees for Home Collection



Variable model which grows with business volume




Automated and scalable system



Real time slot confirmation to patient



Within 1 hr guaranteed on demand service



Key Awards & Recognition



CSR Award 2022



Business Standard Star SME of the year 2022



GAPIO Excellence in Diagnostics Award 2022



Financial Express CFO of the year 2022



CFO100 Roll of Honour 2022



Dr. Om Manchanda honoured and awarded as 'Healthcare Personality of the Year, 2020' by FICCI



ICICI Lombard & CNBC TV18 India Risk Management Awards 2022 – Healthcare



EY Entrepreneur of The Year 2019 – Life Sciences & Healthcare

DATAQUEST

Data Quest Technology Award 2015 – Excellence in Implementation of Technology

VCCIRCLE

VC Circle Healthcare Summit 2013 – Best Diagnostic Company

COMPUTERWORLD

Computerworld Honors Laureate Program, 2012

FROST & SULLIVAN

Frost and Sullivan 4th Annual India Healthcare Excellence Award, 'Diagnostic Service Provider Company of the Year 2012'

FRANCHISE INDIA
Ideas For Tomorrow®

Franchise India Excellence Award in Hall of Fame Category (2011, 2012)



Franchisor of the Year (Healthcare) - Franchise Plus Awards 2010



Padma Shri – (Hony) Brig. Dr. Arvind Lal (2009)

Contact Us

About Dr. Lal PathLabs Limited (DLPL)

Dr. Lal PathLabs Limited is one of India's leading consumer healthcare brand in diagnostic services.

It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates. The catalogue of services includes 491 test panels, 2,675 pathology tests and 1,947 radiology and cardiology tests as on March 31, 2022.

As on March 31, 2022, DLPL's has 277 clinical labs (including National Reference Lab at Delhi & Regional Reference Lab at Kolkata), 4,731 Patient Service Centers (PSCs) and 10,599 Pick-up Points (PUPs). In FY21 & FY22, DLPL collected and processed approximately 49.7 million samples and 66 million samples from approximately 20.3 million and 27.3 million patients, respectively.

Additional information on Dr. Lal PathLabs Limited: Corporate Identification No: L74899DL1995PLC065388

Website: <https://www.lalpathlabs.com>

**For further
information
please contact:**

Ved Goel / Rajat Kalra

Dr. Lal PathLabs Limited

Tel: +91 124 301 6500

Fax: +91 124 423 4468

E-mail: ved.goel@lalpathlabs.com / rajat.kalra@lalpathlabs.com

Siddharth Rangnekar / Nishid Solanki

CDR India

Tel: +91 22 66451209 / 1221

Fax: +91 22 66451213

Email: siddharth@cdr-india.com / nishid@cdr-india.com